Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 4;24(1):119.
doi: 10.1007/s10238-024-01381-5.

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights

Heng Joo Ng  1 , Maaz Kamal Alata  2 , Quang The Nguyen  3 , Phu Huynh Duc Vinh  3 , Jing Yuan Tan  1 , Chieh Lee Wong  4   5
Affiliations
Review

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights

Heng Joo Ng et al. Clin Exp Med. .

Abstract

Patients with hematologic malignancies (HMs) are at a significantly higher risk of contracting COVID-19 and experiencing severe outcomes compared to individuals without HMs. This heightened risk is influenced by various factors, including the underlying malignancy, immunosuppressive treatments, and patient-related factors. Notably, immunosuppressive regimens commonly used for HM treatment can lead to the depletion of B cells and T cells, which is associated with increased COVID-19-related complications and mortality in these patients. As the pandemic transitions into an endemic state, it remains crucial to acknowledge and address the ongoing risk for individuals with HMs. In this review, we aim to summarize the current evidence to enhance our understanding of the impact of HMs on COVID-19 risks and outcomes, identify particularly vulnerable individuals, and emphasize the need for specialized clinical attention and management. Furthermore, the impaired immune response to COVID-19 vaccination observed in these patients underscores the importance of implementing additional mitigation strategies. This may include targeted prophylaxis and treatment with antivirals and monoclonal antibodies as indicated. To provide practical guidance and considerations, we present two illustrative cases to highlight the real-life challenges faced by physicians caring for patients with HMs, emphasizing the need for individualized management based on disease severity, type, and the unique circumstances of each patient.

Keywords: COVID-19; Hematological malignancies; Immunocompromised; Immunosuppressed; Lymphomas; Omicron.

PubMed Disclaimer

Conflict of interest statement

Following the International Committee of Medical Journal Editors’ (ICMJE) guidelines, Heng Joo Ng and Chieh Lee Wong report receiving consulting fees and honoraria for lectures and presentations from AstraZeneca. Quang The Nguyen reports receiving consulting fees from AstraZeneca. Phu Huynh Duc Vinh reports receiving consulting fees and honoraria for lectures and presentations from AstraZeneca and Novartis. Maaz Kamal Alata reports receiving honoraria for lectures and presentations for AstraZeneca, Pfizer, and Astellas Pharma. Additionally, he reports receiving meeting attendance support from Astellas Pharma, NewBridge Pharmaceuticals, Merck, and Gilead. Jing Yuan Tan has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.

Figures

Fig. 1
Fig. 1
Summary of COVID-19 clinical history/timeline
Fig. 2
Fig. 2
Summary overview of HM disease characteristics, common treatment modalities, and COVID-19-related risks [–51]
Fig. 3
Fig. 3
Factors identified to be associated with poor COVID-19 vaccine response [–93]
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Suligowski R, Ciupa T. Five waves of the COVID-19 pandemic and green–blue spaces in urban and rural areas in Poland. Environ Res. 2023;216: 114662. - PMC - PubMed
    1. Martella M, Peano A, Politano G, Onorati R, Gianino MM. Paediatric hospitalizations over three waves of COVID-19 (february 2020 to may 2021) in Italy: determinants and rates. PeerJ. 2023;11: e15492. - PMC - PubMed
    1. Anscombe C, Lissauer S, Thole H, Rylance J, Dula D, Menyere M, et al. A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study. BMC Infect Dis. 2023;23:79. - PMC - PubMed
    1. Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, et al. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg Microbes & Infect. 2023;12:2155250. - PMC - PubMed
    1. Dhama K, Nainu F, Frediansyah A, Yatoo Mohd I, Mohapatra RK, Chakraborty S, et al. Global emerging Omicron variant of SARS-CoV-2: impacts, challenges and strategies. J Infect Public Health. 2023;16:4–14. - PMC - PubMed